Search Results

You are looking at 31 - 40 of 260 items for :

  • "oxaliplatin" x
  • Refine by Access: All x
Clear All
Full access

Margaret A. Tempero

disease, and (3) adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it. Presenting these updates was Margaret A. Tempero, MD, Professor of Medicine, and Director of the UCSF Pancreas

Full access

Presenter: Eileen M. O’Reilly

regimen is mFOLFIRINOX (oxaliplatin 85 mg/m 2 , leucovorin 400 mg/m 2 , irinotecan 150 mg/m 2 , and 5-FU infusion 2.4 g/m 2 over 46 hours, without bolus, given every 2 weeks for 12 cycles). 5 This regimen was compared with single-agent gemcitabine 1000

Full access

Christopher Nevala-Plagemann, Siddharth Iyengar, Andrew D. Trunk, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna

cohort, we selected patients who received a standard first-line chemotherapy doublet defined as 5-FU/oxaliplatin (FOLFOX), capecitabine/oxaliplatin (CAPEOX), or 5-FU/irinotecan (FOLFIRI). Within this group, only patients who were documented as having RAS

Full access

Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven

: Fluoropyrimidine, platinum, and irinotecan (eg, FOLFIRINOX [5-FU/leucovorin/oxaliplatin/irinotecan]) Regimens with gemcitabine and nab-paclitaxel Gemcitabine monotherapy Other regimens Predictor Preselection Predictors were selected based on

Full access

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman

myelosuppressive agent. Error bars indicate 95% CI. Abbreviations: 5-FU, 5-fluorouracil; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AC, doxorubicin, cyclophosphamide; CRC, colorectal cancer; FOLFOX4/mFOLFOX6, folinic acid, 5-fluorouracil, oxaliplatin

Full access

Presenter: Margaret A. Tempero

, patients with metastatic pancreatic cancer were randomly assigned to receive gemcitabine or a combination chemotherapy regimen consisting of oxaliplatin/irinotecan/fluorouracil/leucovorin (FOLFIRINOX). 4 To be enrolled, patients were required to have an

Full access

Axel Grothey and Alan P. Venook

IDEA trial has provided results that will be very helpful for clinicians. 2 IDEA was a combined analysis of 6 individual studies that determined whether 3 months of adjuvant oxaliplatin-based therapy was as effective as, and less neurotoxic than, 6

Full access

Peyman Haghighat and Tanios Bekaii-Saab

Kang WK Kwon JM . Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma . Ann Oncol 2007 ; 18 : 88 – 92 . 20. Bamias A Papamichael D Syrigos K . Phase II

Full access

Ahmed Abdalla, Amr Aref, Amer Alame, Mohamad Barawi, Danny Ma, and Zyad Kafri

FOLFOX or used capecitabine and oxaliplatin as an induction regimen. We are conducting a phase 2 prospective clinical trial to evaluate the use of 6 cycles of FOLFOX as TNT in patients with T2-T3/N0-N+. Patients and Methods: Patients with T2-T3/N0-N

Full access

Jessica A. Davis, Zhanglin Lin Cui, Madiha Ghias, Xiaohong Li, Robert Goodloe, Astra M. Liepa, Kenyon Ogburn, and Lisa M. Hess

(95% CI: 12.07, 13.6). The most common 1L regimens were fluoropyrimidine + oxaliplatin (n=651, 22.4%), platinum (ie, cisplatin or carboplatin) + taxane (n=511, 17.5%), and single-agent fluoropyrimidine (n=280, 9.6%). 1,230 patients received second line